Table 3.
Variable | Crude OR (95% CI) | Adjusted OR (95% CI) |
---|---|---|
Age at enrollment | 1.03 (0.41–2.63) | 0.99 (0.94–1.05) |
Male sex | 2.59 (1.19–5.64) | 2.19 (0.77–6.27) |
dcSSc subset | 3.19 (1.41–7.61) | 2.31 (0.67–7.97) |
Duration of disease every 1 year | 0.99 (0.89–1.11) | 1.02 (0.91–1.15) |
BMI at onset | 0.59 (0.48–0.74) | 0.60 (0.48–0.75)* |
Anti-topoisomerase I antibody | 4.83 (1.11–43.65) | 3.16 (0.39–25.92) |
High CRP | 2.89 (1.30–6.33) | 3.18 (1.06–9.54)* |
Vitamin D insufficiency | 0.34 (0.14–0.78) | 0.47 (0.14–1.59) |
Anemia at onset | 3.99 (1.78–9.32) | 2.39 (0.87–6.54) |
Prednisolone at enrollment | 1.75 (0.82–3.80) | 1.04 (0.91–1.18) |
95%CI 95% confidence interval, dcSSc diffuse cutaneous systemic sclerosis, BMI body mass index, ESR erythrocyte sedimentation rate, CRP C-reactive protein.
*p < 0.001.